Halozyme Therapeutics to host a meeting for analysts and investors

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 15 in New York. During the meeting, Halozyme’s management will present a review of its proprietary product development pipeline, business alliances with Roche and Baxter, and new discoveries in research.

Presenters at the meeting will include Jonathan Lim, M.D., president and CEO, Gregory I. Frost, Ph.D., chief scientific officer, Robert Little, chief commercial officer, and Doug Muchmore, M.D., vice president, endocrinology clinical development. Additional members of the management team will also be attending the meeting.

Halozyme will conduct a live webcast of the presentations beginning at 12:30 p.m. EDT. To access the webcast over the Internet, please go to the company Web site at www.halozyme.com. An archive of the presentation will be available on Halozyme’s Web site shortly after the conclusion of the meeting.